Subscribe
Call Us: 02380 97 07 33

Drug Safety Alert – Dronedarone

Dronedarone (Multaq▼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg twice daily.

Dronederone was only approved by NICE as a second line drug in August 2010. Use of dronedarone may be associated with:

  • an elevated risk of worsening, or new-onset, heart failure
  • liver toxicity

Patients should be asked to be vigilant for the symptoms of heart failure or liver toxicity during treatment, and should undergo regular liver-function testing.

More advise for healthcare professional can be found here.

Leave a Reply

Disclaimer

The information on this site is provided 'as is' Whilst we stake our reputation on producing the most accurate information (and employ reasonable care and skill in providing this site's content), we cannot warrant that the information is accurate, complete and up to date. Neither can we guarantee uninterrupted performance and durability.
Click here to read our complete terms and conditions.